.jpg?format=webp&width=780)
Trifluoperazine (TFP) is a typical antipsychotic primarily used to treat schizophrenia. This study aimed to evaluate whether TFP can be used as a therapeutic agent against nasopharyngeal carcinoma (NPC) and identify its underlying molecular mechanisms. The data revealed that TFP decreased NPC cell viability in a dose‐dependent manner. In addition, TFP inhibited the invasion and migration of NPC tumour cells. An in vivo study also demonstrated the anticancer effects of TFP. RNA sequencing revealed several anticancer molecular mechanisms following TFP administration. The antipsychotic drug TFP could be a potential therapeutic regimen for NPC treatment.
Like
Save
Share